Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Core Insights - Regeneron Pharmaceuticals, Inc. is valued at $81.6 billion and has a portfolio of nine marketed drugs, including Eylea and Dupixent, with fiscal fourth-quarter earnings for 2025 expected to be announced on January 30 [1] Financial Performance - Analysts predict a profit of $8.06 per share for the upcoming quarter, representing an 18.6% decline from $9.90 per share in the same quarter last year [2] - For the full fiscal year, EPS is expected to be $34.76, down 10% from $38.62 in fiscal 2024, with a further decline to $33.50 anticipated in fiscal 2026 [3] Stock Performance - Regeneron stock has underperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with REGN shares only increasing by 6.3% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund's 11.6% returns in the same timeframe [4] Challenges and Recent Developments - The company's underperformance is attributed to challenges such as increased scrutiny of drug pricing, regulatory uncertainty, and competition from larger pharmaceutical companies [5] - Following the Q3 results announcement, REGN shares rose by 11.8%, with adjusted EPS of $11.83 surpassing Wall Street expectations of $9.44, and revenue of $3.8 billion exceeding the forecast of $3.6 billion [5] Analyst Ratings - The consensus opinion on REGN stock is moderately bullish, with a "Moderate Buy" rating overall; 17 out of 27 analysts recommend a "Strong Buy," while two suggest a "Moderate Buy," seven give a "Hold," and one recommends a "Moderate Sell" [6] - The average analyst price target for REGN is $797.92, indicating a potential upside of 4.5% from current levels [6]